Novavax (NVAX) EBITDA (2010 - 2026)
Novavax (NVAX) posted quarterly EBITDA of -$15.4 million for Q1 2026, down 102.99% year-over-year from $515.5 million in Q1 2025, and down 208.43% quarter-over-quarter from $14.2 million in Q4 2025.
Novavax (NVAX) EBITDA (2010 - 2026) Analysis & Trends
Novavax's EBITDA history runs 17 years deep, the most recent figure standing at -$15.4 million for Q1 2026.
- In Q1 2026, EBITDA fell 102.99% year-over-year to -$15.4 million; the TTM figure through Mar 2026 stood at -$78.1 million (down 119.0% YoY), while the FY2025 annual figure was $452.8 million, up 281.9% from the prior year.
- EBITDA for Q1 2026 stood at -$15.4 million, down from $14.2 million in the prior quarter.
- The five-year high for EBITDA was $515.5 million in Q1 2025, with the low at -$483.0 million in Q2 2022.
- The 5-year median for EBITDA is -$127.2 million (2022), against an average of -$60.2 million.
- The sharpest annual moves came in 2023 and 2025: EBITDA slumped 249.44% in 2023, then surged 455.94% in 2025.
- Novavax's EBITDA stood at -$243.9 million in 2022, then climbed by 24.73% to -$183.6 million in 2023, then grew by 28.59% to -$131.1 million in 2024, then soared by 110.86% to $14.2 million in 2025, then plunged by 208.43% to -$15.4 million in 2026.
- Business Quant data shows NVAX's EBITDA at -$15.4 million in Q1 2026, $14.2 million in Q4 2025, and -$178.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Novavax | 1.33 Bn | 607.37 Mn | 42.45 Mn | -54.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -54.91 Mn |
| Mar 31, 2026 | -15.43 Mn |
| Dec 31, 2025 | 14.23 Mn |
| Sep 30, 2025 | -178.02 Mn |
| Jun 30, 2025 | 101.07 Mn |
| Mar 31, 2025 | 515.51 Mn |
| Dec 31, 2024 | -131.08 Mn |
| Sep 30, 2024 | -134.02 Mn |
| Jun 30, 2024 | 161.00 Mn |
| Mar 31, 2024 | -144.83 Mn |
| Dec 31, 2023 | -183.57 Mn |
| Sep 30, 2023 | -125.63 Mn |
| Jun 30, 2023 | 55.46 Mn |
| Mar 31, 2023 | -312.77 Mn |
| Dec 31, 2022 | -243.88 Mn |
| Sep 30, 2022 | -127.19 Mn |
| Jun 30, 2022 | -482.96 Mn |
| Mar 31, 2022 | 209.29 Mn |
| Dec 31, 2021 | -824.97 Mn |
| Sep 30, 2021 | -307.14 Mn |